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Target Audiences
This activity is designed to meet the educational needs of physicians, pharmacists, and nurses in managed care.
Overall Goal
The overall goal of this supplement is to provide health care professionals with information regarding recent advances in multiple sclerosis management, ways to optimize the use of disease-modifying therapies, and strategies to improve costbenefit and risk-benefit outcomes in patients with multiple sclerosis.
Learning Objectives
After completing this activity, the participant should be better able to: 1. Compare the relative risks and benefits of novel and emerging therapies for multiple sclerosis with those of existing disease-modifying therapies, including short-term and long-term safety and efficacy, as well as implications for managed care 2. Evaluate unique mechanisms of action among current and emerging disease-modifying therapies and how to apply the science to practice 3. Assess the literature pertaining to adherence with injectable disease-modifying therapies and the potential influence of oral disease-modifying therapies in patient adherence and compliance
Funding
There is no fee for this activity as it is sponsored by PRIME, Inc., through an independent educational grant from Teva Neuroscience.
OBJECTIVES: To review (a) recent advances in MS management, (b) strategies to optimize the use of disease-modifying therapies for MS, (c) costs of current MS therapies, (d) strategies to promote adherence and compliance to disease-modifying therapies, and (e) potential strategies for managed care organizations to improve care of their MS patient populations and optimize clinical and economic outcomes.
SUMMARY: Advances in magnetic resonance imaging and newer therapies have allowed earlier diagnosis and reduction of relapses, reduction in progression of disability, and reduction in total cost of care in the long term. Yet, even with the incorporation of new disease-modifying therapies into the treatment armamentarium of MS, challenges remain for patients, providers, caregivers, and managed care organizations as they have to make informed decisions based on the properties, risks, costs, and benefits of each individual drug as part of an individualized shared decision-making process. Case management and collaborative practice models, which incorporate self-management, medication therapy, formulary management, and continuous education, while promoting symptom management, medication adherence, and a health-promoting lifestyle, are important in the overall management of MS and can provide outcomes-based interventions aimed at controlling costs while maximizing treatment efficacy. M ultiple sclerosis (MS) is a chronic, complex, and often disabling disease of the central nervous system (CNS) with a variable clinical course. Patients with MS exhibit the pathological hallmarks of inflammation, demyelination, gliosis, axonal degeneration, and dysfunction resulting from dysregulation of the immune system. 1, 2 Although the intercompartmental relationships and hierarchy of events are not fully understood, it is suggested that the inflammatorydemyelinating component predominates in the relapsingremitting phase of the disease and is manifested by recurrent episodes of exacerbation and remission; whereas, the neurodegenerative component, leading to extensive neuronal damage in the brain, occurs in parallel to the inflammatory process in progressive stages of the disease. 3 MS affects more than 2.1 million people worldwide and over 400,000 individuals in the United States, with about 200 new cases diagnosed every week. 4 Although it can affect individuals at any age, MS is usually diagnosed between the ages of 20-40 years 5 and is approximately 3 times more common in women than in men. 6 Although MS occurs in most ethnic groups, it is more common in Caucasians of northern European ancestry and has been shown to be more common at northern latitudes that are farther from the equator. 4 As a leading cause of disability in young adults, MS substantially affects an individual's quality of life and imposes a major financial burden on the patient, family, and health care system. 7, 8 Although the etiology of MS is not yet completely understood and is a topic of ongoing research interest, it has been proposed that the disease may be attributed to a combination of environmental, infectious, and immunological triggers in genetically susceptible individuals. 9, 10 For example, reduced exposure to sunlight (or vitamin D deficiency), 11 smoking, 12 and Epstein-Bar virus (EBV) infection 13 have been identified as risk factors for development of MS and at times may act as poor prognostic indicators. Additionally, studies indicate that about 40% of MS patients carry the HLA-DR2 haplotype, suggesting a genetic predisposition associated with this gene. 14, 15 However, not all individuals who carry the HLA-DR2 haplotype will develop MS.
Immunopathogenesis of Multiple Sclerosis
The widely accepted theory for the immunopathogenesis of MS is that it is an inflammatory autoimmune disorder mediated by activation of circulating autoreactive T-cell lymphocytes in the peripheral blood. Activation of these cells may lead to upregulation of specific adhesion molecules on their surfaces (i.e., very-late activation antigen-4, VLA-4[α4β1]), which allows them to interact with vascular cell adhesion molecule-1 (VCAM-1), a protein expressed on capillary endothelia cells in the blood brain barrier (BBB). This interaction triggers the T-cell 10% of MS patients, is a progressive disease that worsens over time from the initial event, with no clear distinction between relapse and remission. PRMS differs from PPMS in that it is characterized by disease progression from onset with occurrence of clear, acute relapses. Benign (or mild) MS, considered a subset of RRMS, occurs in about 10% of MS patients. In this subtype, patients experience an initial mild disability event and a long remission period that can last for years until a second event occurs. 22 While these patients may not experience clinical symptoms during their remission period, MRI scans typically show positive activity or lesions in the CNS. 20, 23 For many patients with MS, the first presentation is a clinically isolated syndrome (CIS), defined as a single neurological episode caused by inflammation in 1 or more sites within the CNS and lasting at least 24 hours, with features suggestive of MS. The risk for individuals who experienced a CIS to develop MS is determined by the presence of MRI-detected brain lesions: patients with demyelinating lesions on MRI are at high risk (60%-80%) to develop MS, and patients with normal MRI are at lower risk (about 20%). 24 
■■ Predicting Outcomes and Optimizing Costs in Multiple Sclerosis
Because MS is diagnosed at a relatively younger age (20 to 40 years), it may represent a greater economic burden than other chronic diseases and poses substantial impact on health, quality of life, productivity, and employment over many years. In a cross-sectional study of 1,909 patients (mean age 49 years; mean time since diagnosis 13 years), the average total annual cost per patient in the United States was estimated at $47,000 (in 2004 dollars). Of this, 62.8% was for direct medical costs and 37.2% for nonmedical costs. The largest cost items were disease-modifying therapies (DMTs; 21%), followed by the need for informal care from family and friends (12%) and longterm production losses (10%). 8 Additionally, with the approval of several new, relatively expensive oral DMTs for MS in recent years, the average annual cost of medications for an MS patient in the United States has increased, ranging from $35,000 to $45,000 in 2011. 25 The increase in price of medication is likely to continue to rise due to the expected incorporation of even more new therapies.
The high cost of therapy is only part of the economic burden of MS. Various studies have shown that MS-related cost is largely dependent on the overall health, functional capacity, and level of disability in individual patients. 7, 8, 26, 27 Currently, the Kurtzke Expanded Disability Status Scale (EDSS) 28 is the gold standard and most widely used method in clinical trials to quantify disability in MS and to measure the effect of therapeutics on disability. 28 The EDSS scores the disease burden or disability in a nonlinear scale ranging from 0 to 10.0 (0 = normal neurological exam; 10.0 = death due to MS). Lower scores of 1.0 to 4.5 refer to the disability of patients with MS who are fully ambulatory, measured in both upper and lower extremities; higher scores of 5.0 to 9.5 describe impairment lymphocytes to secrete chemokines, which leads to their migration toward the BBB where they release proteolytic enzymes called matrix metalloproteinases (MMPs). This release causes the extracellular matrix and basement membranes to degrade, allowing the activated lymphocytes to migrate through the BBB into the CNS compartment and in turn interact with other antigen-presenting cells (e.g., microglia, dendritic cells, B-cells). Further activation processes lead to the secretion of inducible nitric oxide synthase (iNOS), an enzyme that is involved in production and release of nitric oxide, which is a major contributor to the demyelination of nerve fibers leading to chronic neurodegeneration. 16 
Signs and Symptoms
The primary symptoms of MS resulting from disruption and damage to myelin and nerve fibers in the CNS, can vary by patient and may change or fluctuate over time. Although for many years MS has been considered a white matter disease (i.e., involving sensory and motor findings), with the advancement of magnetic resonance imaging (MRI), it is now well recognized that MS lesions occur in grey matter as well (i.e., involves cognitive behavior), 17 leading to a myriad of complex symptoms. Some of the more common primary symptoms may include vision problems, fatigue, paresthesia, bladder/ bowel/sexual dysfunction, gait problems, spasticity, dizziness/ vertigo, pain, depression, and cognitive dysfunction. Less common symptoms may include headache, hearing loss, seizures, tremors/incoordination, and speech/swallowing difficulties. 18 These symptoms may lead to additional complications, known as secondary (e.g., urinary tract infections, loss of muscle tone, decreased bone density, shallow breathing, pressure sores) and tertiary (e.g., social, vocational, and psychological complications) symptoms, which can be a significant challenge for health care professionals to effectively treat and manage. 18 
Clinical Subtypes of Multiple Sclerosis
Patients with MS typically experience 1 of 4 subtypes: (1) relapsing-remitting MS (RRMS), (2) secondary progressive MS (SPMS), (3) primary progressive MS (PPMS), or (4) progressive relapsing MS (PRMS). 19 Each of the patterns of disease can vary in its severity and intensity and can change over time. RRMS is the most common subtype, affecting over 80% of patients initially diagnosed with MS. In this subtype, patients develop a clearly defined clinical event (relapse), followed by partial or complete recovery that may last for a period of months or years (remission) until the next episode occurs, usually with increasing disability levels. 20 It is hypothesized that the inflammatory component drives the relapses, and the degenerativedemyelinating component drives the increasing disability. 21 If untreated for several years, the relapsing-remitting (RR) subtype can transition to the secondary progressive (SP) subtype. This transition occurs in about 40% of RRMS patients and leads to progressively increasing disability with less frequent remissions or recovery episodes. PPMS, which occurs in about the scale, they will require the assistance of a cane, a walker, a wheelchair, and eventually will be bed-bound. As MS progresses and the level of disability increases, total (direct and indirect) cost of care will increase as well (Figure 1) . 29 It is, therefore, important to recognize and educate patients that early intervention slows the development of disability, thereby reducing the predicted costs of care and improving clinical outcomes in patients with MS. 29 Another important aspect relating to cost of care is that atrophy and axonal degradation can be detected by MRI lesion activity more frequently than clinical relapses and, therefore, can be measured earlier in the disease process even when clinical symptoms are not apparent (Figure 1) . 29 This means the cost of care may be higher in early disease stages due to more frequent MRI scans. In more progressive stages of the disease, physicians may rely less on MRIs because the progression may be more apparent in clinical examination. 30 Despite the higher initial costs, early diagnosis and intervention strategies can optimize outcomes and costs in the long-term management of patients with MS.
Because of the high costs associated with MS, managed care organizations (MCOs) and other entities seek methods to lower costs and reduce administrative overhead, while measurably improving quality of care and patient outcomes. In order to of ambulation (lower extremities only). 28 Consistent with clinical trial data, it is now generally accepted in practice that patients with RRMS who have lower EDSS scores will respond better to treatment than patients who score higher on the EDSS scale. 20 A recent systematic meta-analysis of 29 economic burden studies, which evaluated the relationship of level of disability to the total MS-related costs in a number of European countries, the United States, and Canada suggests a clear increase in costs associated with increase in disease severity as measured by the EDSS score. 7 Notably, the increase in costs was associated with increase in relapse occurrence in all studies included in the analysis. 7 Although the distribution of costs varied between countries, medications and hospitalizations were the two major components of total MS costs in the United States. 7 Yet the meta-analysis review could not infer on the potential differences in economic costs between the different disease subtypes and on the potential cost offsets associated with widespread use of DMTs. Additional studies have demonstrated that while predicted costs increase with the progression of disease, early intervention significantly reduces the overall cost in patients with MS. 8, 26, 27 This corresponds with the fact that MS patients can be fully ambulatory for years; however, once they reach an EDSS score of 6 and progress with small increments in medications. While such biomarkers are currently available in other diseases such as cancer, they are still in early stages of development for MS. In the future, biomarkers may be utilized in early disease detection, long-term prognosis, detection of potential new therapeutic targets, and to determine treatment response.
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Progression of Disability and Predicted Costs for Multiple Sclerosis
Source: Burks J. MS: the treatment paradigm, a pathway to success for improved patient outcomes. 29 This curve is based on an estimation of the decrease for early treatment of about 40% at each range of EDSS. a Curve is based on an estimation of the decrease in cost for early treatment of about 40% at each range of EDSS. b Does not include current drug costs. CIS = clinically isolated syndrome; EDSS = Expanded Disability Status
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Process metrics and outcomes metrics are available to pharmacists and case managers to evaluate and manage patients with MS. 25 Assessment of outcomes provides the framework for future planning, and careful and accurate assessment of outcomes of interventions may improve the ability to assist MS patients in establishing short-term and long-term goals. Health care professionals, together with managed care pharmacists and nurse case managers have the responsibility to identify and utilize meaningful outcome measures. Thus, it is important determine whether patients with MS receive appropriate, comprehensive health care, major stakeholders in health care have searched for quality indicators to measure quality of care. Since the EDSS scores are a more useful measure of outcomes in randomized clinical trials (RCTs), a comprehensive set of quality indicators have been proposed to assess processes and quality of care of persons with MS outside of clinical trial settings. These indicators consider factors such as relapse rates, MRI activity, quality of life, and various other factors (e.g., appropriateness and timeliness of the diagnostic work-up, bladder dysfunction, cognitive dysfunction, depression, DMT usage, fatigue, integration of care, spasticity) to evaluate management of individual patients. 31 Additionally, extensive research is currently being done to find effective biomarkers that will predict which patients will have a favorable response to specific that each intervention has a planned outcome as well as the methodology to evaluate that outcome.
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■■ Disease-Modifying Therapies Available and experimental treatment options for patients with MS have greatly increased over the last 2 decades due to extensive research and enhanced understanding of the mechanisms and immunopathogenesis of the disease. Although MS is not currently curable, the available approved DMTs may slow the progression of the disease and help manage some symptoms. In addition, current investigational therapies are showing promise to improve outcomes in MS patients. Table 1 summarizes current indications and mechanisms of action associated with these new and emerging therapies. Currently, 9 DMTs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of MS and CIS. Interferons (IFN) β-1a and β-1b (each in 2 different formulations) and glatiramer acetate are well established as "platform" or first-line immunomodulatory therapies for relapsing forms of MS and are administered by subcutaneous or intramuscular injections. The cell adhesion inhibitor, natalizumab, and the immunosuppressive medication, mitoxantrone, are mainly used as second-line therapies and are given by intravenous infusion under the supervision of a health care professional. However, as the clinical burden of chronic injections or infusions is high for patients, there has been an ongoing quest for oral DMTs for relapsing MS, which would be easier to administer and might improve medication adherence. 35 The first oral medication for relapsing forms of MS, fingolimod, was approved in late 2010, and oral teriflunomide received regulatory approval in September 2012. 36 Additional therapies for which phase 3 data are available include the oral agents BG-12 (dimethyl fumarate) and laquinimod, as well as the anti-CD52 monoclonal antibody, alemtuzumab. Several other oral agents and monoclonal antibodies that target specific components of the immune system are in earlier stages of their clinical development. 37 
Mechanism of Action of Current and Emerging DMTs
Many of the available DMTs block the migration of the inflammatory T lymphocytes into the brain and spinal cord, each via a different mechanism of action and anatomical location.
Fingolimod, also known as FTY720, is a small molecule designed to inhibit the sphingosine-1-phosphatase (SIP) receptor and thereby prevent migration of the autoreactive T lymphocytes from the peripheral lymphoid organs into the blood circulation, restricting their access to the brain and spinal cord. 38 Fingolimod may cause lymphopenia as a result of the sequestration of lymphocytes within the lymph nodes. The clinical efficacy and safety of fingolimod in patients with RRMS were evaluated in 2 large, randomized phase 3 trials, FREEDOMS 39 and TRANSFORMS. 40 Natalizumab is a recombinant humanized monoclonal antibody that acts as a selective adhesion molecule inhibitor by binding to the α4 subunit of VLA-4[α4β1] integrins on the BBB. Integrin inhibition prevents migration of T-lymphocytes into the brain parenchyma. [41] [42] [43] IFNβ is thought to prevent migration of the inflammatory cells into the CNS by inhibiting matrix metalloproteinase enzymes on the BBB. 44, 45 Other DMTs regulate the inflammatory response that occurs within the CNS following reactivation of autoreactive T lymphocytes that have penetrated the CNS compartment. Glatiramer acetate is known to induce a population of T and B regulatory cells that suppress reactivated T lymphocytes. Glatiramer acetate is approved for first-line treatment in both RRMS and CIS. [46] [47] [48] [49] The recently approved teriflunomide is a novel oral agent indicated for the treatment of relapsing forms of MS. Teriflunomide is a selective reversible inhibitor of dihydroorotate dehydrogenase and blocks de novo pyrimidine synthesis in rapidly proliferating cells, including autoreactive T and B lymphocytes, resulting in its presumed immunomodulatory effects. This oral agent is the active metabolite of leflunomide, an anti-inflammatory drug that is also used in patients with rheumatoid arthritis. 50 In a recent randomized phase 3 clinical trial (TEMSO), teriflunomide significantly reduced annualized relapse rates and MRI evidence of disease activity with an effect on disability progression, relative to placebo in patients with relapsing MS. 51 BG-12 is another oral agent that, in addition to its antiinflammatory effects, is thought to exert a neuroprotective action via activation of the Nfr-2 pathway. Two recently completed large multicenter phase 3 trials (DEFINE [52] [53] [54] and CONFIRM 55, 56 ) evaluated the efficacy and safety of BG-12 in patients with relapsing-remitting forms of MS. BG-12 demonstrated significant reduction in the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI when compared with placebo. Based on these positive data, the FDA is currently reviewing the New Drug Application (NDA) for this oral therapy.
Laquinimod, a derivative of linomide, is an oral once-daily investigational immunomodulatory molecule. Its exact mechanism of action is incompletely understood, but it is believed to enhance secretion of anti-inflammatory cytokines, which decreases secretion of proinflammatory cytokines, and it is also thought to upregulate brain-derived neurotrophic factor. 57 Laquinimod has been evaluated in 2 global phase 3 clinical trials (ALLEGRO and BRAVO) over 2 years. In both of these placebo-controlled trials, laquinimod slowed the progression of disability and brain atrophy and reduced the rate of relapse in patients with RRMS. 58, 59 An additional phase 3 trial (CONCERTO) will be initiated to further evaluate 2 doses of laquinimod (0.6 milligrams [mg] and 1.2 mg) in approximately 1,800 patients for up to 24 months and to confirm its utility in relapsing forms of MS prior to seeking FDA approval.
Alemtuzumab is a humanized monoclonal antibody that profoundly depletes inflammatory lymphocytes by targeting patient populations, and with varying study methodologies. It is also important to note that during the last decade extensive research in patients with earlier or more benign disease and lower EDSS scores has highlighted the importance of early intervention with DMTs for reducing relapse rates and slowing disease progression. 67 Head-to-head randomized comparison trials using similar methodologies, in similar patient populations, such as the REGARD (subcutaneous IFNβ-1a vs. glatiramer acetate), 68 BEYOND (IFNβ-1b vs. glatiramer acetate), 69 and TRANSFORMS (fingolimod vs. intramuscular IFNβ-1a) trials 40 may allow better comparisons between different treatments. In a 1-year follow-up of the TRANSFORMS trial, oral fingolimod was superior to IFNβ with respect to relapse rates and MRI outcomes; however, the treatments were similar with regard to disability. 40 Select additional direct comparative randomized trial data for DMTs in the treatment of MS are summarized in Table 3 . Due to the limited availability of comparative data, health care professionals should follow practice guidelines and utilize their clinical judgment to determine the treatment option that best fits the needs and preferences of individual patients.
■■ Risks Associated with Current and Emerging DMTs
As new therapies enter the marketplace, their safety and risks are continuously under evaluation in post-marketing stages, particularly considering the relatively limited number of patients enrolled in clinical trials, exclusion criteria, and duration of exposure to the drugs. Care providers should be aware of associated safety issues with new and emerging therapies and should remain informed as the safety profiles develop as a result of post-marketing data.
Generally, treatment with the traditional first-line DMTs, IFNβs and glatiramer acetate, is considered to be relatively safe. The most frequently reported adverse effects in clinical trials for the different IFNβ formulations include injection-site reactions, flu-like symptoms, fatigue, myalgia, elevation of the cell-surface glycoprotein CD52, which is highly expressed on T-and B-lymphocytes. 60 This agent is currently approved for the treatment of B-cell chronic lymphocytic leukemia.
Two randomized phase 3 clinical trials (CARE-MS I 61 and CARE-MS II
62
) evaluated the efficacy and safety of intravenous alemtuzumab (administered over 5 consecutive days during the first year and over 3 days during the second year) versus subcutaneous IFNβ-1a in patients with active relapsing forms of MS. The CARE-MS I trial, evaluating alemtuzumab in treatment-naïve patients (first-line setting), met its primary endpoint of reduction in relapse rates when compared with IFNβ-1a, yet did not achieve a significant reduction in the progression of disability when compared with IFNβ-1a due to low event rate. 61 Data from the CARE-MS II trial, which evaluated alemtuzumab in patients who relapsed while on first-line therapy (second-line setting), revealed significant reductions in both relapse rates and in sustained accumulation of disability as measured by EDSS scores. After 2 years of therapy, patients treated with alemtuzumab were more than twice as likely to experience disability improvement compared with IFNβ-1a. 62 Alemtuzumab is currently under FDA review for its approval.
■■ Comparing Relative Benefits of Available DMTs
New and emerging DMTs for MS provide both opportunities and challenges for patients, providers, caregivers, and MCOs. As with all formulary decisions involving chronic therapies for complex disease states, it is important to review the overall efficacy and safety profile of products used to treat MS. Table 2 summarizes the pivotal trial data that led to the FDA approval of the currently available DMTs IFNβ-1a, 63, 64 IFNβ-1b, 65 ,66 glatiramer acetate, 48 natalizumab (AFFIRM), 43 fingolimod (FREEDOMS), 39 and teriflunomide (TEMSO). 51 The relative benefits of individual DMTs in terms of effects on relapses and disability are unclear as the individual placebocontrolled trials were performed at different times, in different should be carefully evaluated for signs and symptoms of heart disease. 74, 75 Treatment with fingolimod leads to a broad range of associated safety issues due to its mechanism of action, namely via modulation of S1P receptors, which are involved in multiple biological processes and are present in many organs in the body, including the heart, liver, lungs, and eyes. Although its long-term risk versus benefit profile is not fully defined, adverse effects that have been associated with this therapy include cardiac abnormalities such as bradycardia (slow heart rate) and atrioventricular block, as well as hypertension, hepatic enzyme elevation, respiratory changes, infections, and macular edema. [38] [39] [40] Several fatalities have been reported following treatment with fingolimod; however, the FDA has been unable to conclude that the deaths were related to the drug. 76 The FDA-approved label now requires at least a 6-hour monitoring period after the first fingolimod dose (due to evidence that decreases in heart rate typically occur within 6 hours of the first dose with a maximum effect that may occur as late as 20 hours after the first dose in some patients) and an electrocardiogram prior to dosing and at the end of the observation period. Additionally, fingolimod is now contraindicated in patients with certain pre-existing or recent heart conditions or stroke or who are taking certain antiarrhythmic medications. 76 Observation is also required for patients who have not taken fingolimod for over 2 weeks as they may also be at increased risk for cardiac events. Because this type of evaluation is not required in all therapies, the added costs of electrocardiography and billing of associated physician services should be evaluated and calculated when considering treatment with fingolimod. However, avoidance of office visits and associated costs required for infusion therapy, as well as decreased clinical burden due to oral administration, are potential benefits of fingolimod therapy. liver transaminase enzymes, and hematopoietic abnormalities. [63] [64] [65] [66] The major adverse effects reported in clinical trials for glatiramer acetate were injection-site reactions, which often lead to complaints of lipoatrophy. 68, 69 Despite their mild safety profiles, these treatments reduce relapse rates by only about 30% and may be associated with decreased adherence due to their administration. 70 Intravenous DMTs, such as natalizumab and mitoxantrone (used as second-line therapy for patients with highly active disease or suboptimal response to first-line agents), are associated with more serious and perhaps life-threatening adverse effects. Treatment with natalizumab has been associated with infections, post-infusion reactions, hepatic enzyme abnormalities, and progressive multifocal encephalopathy (PML)-an often fatal demyelinating disease of the CNS. As of October 2012, 285 post-marketing cases of PML have been confirmed among 104,300 patients treated with natalizumab, and 62 of these have been fatal. 71 Risk factors for development of PML in natalizumab-treated MS patients include a positive anti-JCV (John Cunningham [JC] polyomavirus) antibody test, prior use of immunosuppressants, and duration of natalizumab treatment exceeding 24 months. 72 A patient with all 3 risk factors has the highest likelihood of developing PML (1:90). Given that anti-JCV antibodies are found in about 50%-60% of both the general population and MS patients, health care providers should apply risk stratification strategies to their patients receiving natalizumab therapy according to the above mentioned risk factors to facilitate early initiation of optimal therapy and improve treatment decisions. 73 Additionally, it is recommended that patients receiving natalizumab who have had a negative anti-JCV antibody test should be retested every 6 months. The use of the chemotherapeutic immunosuppressant agent mitoxantrone for treatment of MS has decreased due to the associated risk for therapy-related acute leukemia and cardiotoxicity. Patients receiving mitoxantrone therapy
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Trial Name
Comparative Intervention Key Trial Data INCOMIN 110 IFNβ-1b SC q2d vs. IFNβ-1a IM weekly Higher relapse-free rate with IFNβ-1b SC (51%) compared with IFNβ-1a IM (36%; P = 0.03) EVIDENCE 111 IFNβ-1a SC vs. IFNβ-1a IM Higher relapse-free rate with IFNβ-1a SC (56%) vs. IFNβ-1a IM (48%; P = 0.023) REGARD 68 IFNβ-1a SC vs. glatiramer acetate No significant difference in time to relapse BECOME 112 IFNβ-1b SC vs. glatiramer acetate No significant difference in cumulative active lesions between groups BEYOND 69 IFNβ-1b SC vs. glatiramer acetate Similar decline in relapse risk (78%-79%) TRANSFORMS 40 Fingolimod vs. IM IFNβ-1a
Superior efficacy of fingolimod, with respect to relapse rates and MRI outcomes, with no differences with regard to disability, after 1-year follow-up MS CARE I 61 Alemtuzumab vs. IFNβ-1a in first-line setting Higher relapse-free rates in alemtuzumab yet no significant reduction in progression of disability (low event rate) MS CARE II 62 Alemtuzumab vs. IFNβ-1a in second-line setting Significant reductions in relapse rates and in sustained accumulation of disability in alemtuzumab after 2 years of follow-up CAMMS223 113 Alemtuzumab vs. IFNβ-1a
Higher relapse-free rates and reduction in disability in alemtuzumab after a 5-year follow-up IFNβ = interferon beta; IM = intramuscular; MRI = magnetic resonance imaging; q2d = every 2 days; SC = subcutaneous. hyperthyroidism and immune thrombocytopenic purpura (ITP) because this agent ablates T-and B-cells for a prolonged period of time. 61, 62 Additionally, patients are at increased risk for opportunistic infections and malignancies. Perhaps one of the most challenging issues, also due to the depletion of T-and B-cells by alemtuzumab, is the limited utility of subsequent treatments when patients do not adequately respond to treatment with alemtuzumab.
Based on the properties associated with each drug, health care professionals as well as MCOs must make informed choices for their patients or plan members. The opinions and practice patterns of national, regional, and local specialists should become a key component of the evaluation process for newly approved drugs. 80 As practice guidelines 81 and practice patterns are developed and updated, MCOs must continue to develop formularies that provide the most appropriate therapies for their members. This will require ongoing evaluation as new oral drugs for MS enter the marketplace. In addition, careful assessment of the risk-benefit profile of the various agents for relapsing MS should include an individualized approach for each patient as part of a shared decision-making process. Table 4 summarizes the adverse effects associated with available DMTs.
■■ Optimizing Adherence to DMTs to Improve MS Outcomes
Poor adherence is a problematic and challenging issue in the management of many chronic diseases and is often associated with significant consequences in both clinical and economic outcomes. 83 This is particularly true in the case of MS, where treatment with DMTs provides the greatest benefit by reducing relapses and delaying disease progression, and adherence to DMTs is clearly associated with lower risks for disease-related hospitalizations, fewer relapses, and less associated medical costs. 84, 85 Multiple factors have been attributed to nonadherence to MS medications, including mainly drug side effects (e.g., flu-like symptoms, injection-site reactions, fatigue), forgetfulness, and issues related to injections (e.g., fear/anxiety, pain, discomfort), as well as perceived lack of efficacy, financial issues, depression, and curiosity about other therapies. [86] [87] [88] [89] [90] [91] In many cases, patients with MS do not experience significant relapse or new symptoms for months or years after their initial diagnosis, which makes it difficult for them to accept their disease (psychological denial) and the need for routine therapy. Other patients who do acknowledge their disease may have low adherence due to forgetfulness relating to the disease process, or they may deliberately withhold it. 87, 89, 90 In a global survey (MS Choices Survey) among 331 patients who were diagnosed with MS for a year or longer, 31% of overall respondents reported they took a deliberate break from treatment of 1 day or longer, and 19% reported they had stopped taking their medications completely. Treatment discontinuations were most often associated with side effects (42%), emotional fatigue from treatment (13%), practical issues with treatment (9%), lack Key side effects associated with teriflunomide include diarrhea, elevated liver enzymes, nausea, flu-like symptoms, and thinning or loss of hair. 51 In addition, leflunomide (an analogue of teriflunomide) has been associated with teratogenic and embryo-lethal effects in some animal models. [77] [78] [79] Therefore, teriflunomide is considered a Category X in pregnancy, and women of childbearing age must have a negative pregnancy test before starting the drug and use effective birth control during treatment. Care providers should also monitor liver function prior to starting teriflunomide and periodically during treatment. 36 BG-12 has been associated with mild adverse events in clinical trials including flushing (30%-40%) and gastrointestinal symptoms (e.g., diarrhea, nausea/vomiting, abdominal pain; about 20%). The incidence of these events decreased substantially after the first month of therapy. [53] [54] [55] [56] Patients treated with alemtuzumab may develop thyroid disorders, such as P < 0.01) and specialty pharmacy patients (200 days vs. 188 days; P = 0.002); and (c) decrease the incidence of MS relapses from months 0 to 6 (14.0% vs. 9.1%; P = 0.03). This program did not result in improvement in health-related quality of life or work productivity, but patients reported that the program enabled them to improve management of their health. 99 The Treatment OPtimization in MS (TOP MS) study is a large, prospective phase IV study conducted in approximately 3,000 MS patients receiving treatment and medication therapy management (MTM) via specialty pharmacy programs. Assessment of MS therapies at enrollment showed differences in duration of use, number of missed doses, reasons for missed doses, and continuous versus intermittent use. 90 The final study results, anticipated in late 2012, will provide insight into the benefits of compliance and adherence to therapy on health outcomes (e.g., relapses, disability, quality of life, productivity).
90,100
Such a study can assess the influence of MCO involvement on treatment adherence and may highlight the value of optimizing treatment with DMTs for physicians, patients, and MCOs.
Unfortunately, despite adherence and compliance to prescribed medications, optimization and adjustment of treatment combinations, and follow-up visits with specialized health care professionals, available DMTs may still exert only a partial effect in some patients due to unknown factors. A patient's MS status and therapy choice should be carefully assessed upon initiation of treatment and over time, if there is radiographic or clinical evidence of disease progression. An evaluation of the patient's MRI activity and clinical status can also help determine whether current therapy should be continued or new therapy should be considered. 101, 102 Although it is recommended that care providers optimize each treatment prior to switching, care providers should apply clinical guidelines, best clinical judgment, assessment of risk-benefit and cost-benefit profiles, and a shared decision with the patient when determining whether to switch therapies.
The highly important decision of switching to a different therapy may be considered if patients experience any of the following: (a) breakthrough disease (clinical or MRI evidence of disease activity despite treatment), (b) high-titer of neutralizing antibodies to IFNβ, (c) intolerable side effects despite optimized management strategies, or (d) compromised quality of life. 101, 102 When switching from first-line to newer second-line therapies, care providers need to be aware that there may be unknown safety risks because the safety profiles of newer therapies are still evolving.
■■ Conclusions MS is a multifocal demyelinating disease with progressive neurodegeneration caused by an autoimmune response to self-antigens in susceptible individuals. This chronic and unpredictable disease must be managed with a comprehensive strategy that utilizes preventive, medical, rehabilitative, mental health, and long-term care services to assist affected individuals and their families. Because of the young age of diagnosis, of efficacy (9%), or lack of symptoms (6%). 91 When a similar questionnaire was given to 280 neurologists treating patients with MS, it was estimated that only an average of 17% of their patients were taking treatment breaks and that the reason for nonadherence was mainly due to side effects (82%). This suggests that physicians may underestimate the prevalence of poor adherence and may not be fully aware of the underlying reasons for poor adherence to DMTs in their patients. 91 A retrospective cohort study using administrative health care claims in a U.S. commercial managed care population who received DMTs showed that nearly 60% of newly diagnosed MS patients remained untreated after a follow-up period (35.7 ± 17.5 months after diagnosis), while over a quarter of treated patients stopped therapy, and one-sixth experienced treatment gaps despite the risk of disease progression or a return of pre-treatment disease activity. 92 Studies evaluating adherence to injectable MS therapies report that approximately 80% of patients have 80% adherence for the first 6 months, 93 but this decreases to 60% to 76% at 2 to 5 years. 94 Oral agents have a potential advantage over injectable therapies in terms of improving adherence. Generally, oral agents are perceived to be better tolerated, preferred by patients over injectable medications (particularly for those who have anxiety due to needles), and cause less interference with daily activities. However, the use of oral medication is also typically perceived to be less effective than injections and may be easier to forget. The extent to which outcomes of MS patients may be improved with potentially better adherence to oral medications remains to be evaluated. 95 In the long term, poor adherence is associated with poor clinical outcomes that can negatively impact patient quality of life. 96 Improvements in education, consistent reinforcement, and open communication between patients and their care providers, along with management of treatment expectations and minimization of adverse events all play important roles in increasing adherence to DMTs. 87 Education specific to injectable therapies should include ways to manage tolerability such as dose titration and reduction, timing of injections, use of sleep aids, co-administration of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen before and after injections, use of low-dose oral steroids at treatment initiation, and injection techniques. Patients should also be provided support through frequent contact with an MS-specialized nurse or case manager. 87, 97, 98 Programs that promote symptom management, medication adherence, and a health-promoting lifestyle are important in the overall management of MS. One example of a disease therapy management (DTM) program that incorporated both self-management and medication therapy management components within a structured 7-month program was reported to (a) significantly increase adherence to injectable medications for enrolled patients compared with community pharmacy patients (0.92 vs. 0.86; P < 0.001); (b) significantly improve persistence on therapy for both community (220 days vs. 177 days; 
Managed Care Pharmacy Perspectives: Assessing Costs Versus Benefits to Optimize Outcomes
The costs of DMTs have continued to rise in recent years. These increases in cost have made it hard for patients that do not have insurance coverage or do not qualify for assistance from manufacturers to receive DMTs. This continued increase in cost is also increasing the burden on the employers that sponsor the majority of the premium dollars collected by MCOs. The introduction of effective new agents and additional treatment options for the treatment of relapsing forms of MS is a positive development for both the MS community and MCOs. However, as the MS market space gets more crowded, the manufacturers will need to compete among themselves, each having to provide a value proposition to MCOs.
Over the years, a larger portion of prescription drug cost has been shifted to consumers; this increase in cost share to the patients may lead to decreases in DMT compliance and a significantly higher risk of medication discontinuation. [103] [104] [105] [106] A recent study demonstrated a 6-fold higher DMT abandonment rate for MS patients who are enrolled in health insurance plans whose out-of-pocket expenses exceed $200 when compared with those with out-of-pocket expenses of $100 or less. 107 Although the effect of out-of-pocket costs on health outcomes has not been specifically studied in MS, decrease in adherence to IFNβ therapy has been associ¬ated with significantly increased risk of relapses. 108 The goal of MCOs is to provide affordable quality health care to their members. When evaluating new treatments, there should be incremental improvement in health outcomes based on dollars spent when compared with standard of care. Different MCOs have utilized various managed care management tools (e.g., prior authorization, quantity limit) in an attempt to better manage the class. Most MCOs consider DMTs as specialty drugs, although each MCO uses a different definition of specialty drug to define how DMTs are covered. Typically, agents that require administration in the physician's office are covered under the medical benefit (e.g., natalizumab), while DMTs that can be self-administered are covered under the pharmacy benefit (e.g., IFNβ formulations, glatiramer acetate, and the newer oral agents fingolimod and teriflunomide). There is an opportunity to improve formulary management and curb the utilization growth for specialty medications by providing coverage for DMTs under a single benefit, which would lower administrative overhead and improve clinical quality.
Some MCOs require DMTs to be procured through specialty pharmacies to ensure that the medications are handled appropriately and that pharmacists who are knowledgeable in DMTs are available to provide real-time consultation to patients with MS. Some MCOs and specialty pharmacies offer additional disease management programs that work with both patients and physicians in managing issues such as symptoms, depression, adherence, preventive care, and reimbursements. Since 2009, accountability care organizations (ACOs) have been proposed as a novel way to curb rapidly rising health care costs and to the economic burden of MS exceeds other debilitating diseases that occur later in life. Despite advances in MRI and therapy, which have allowed earlier diagnosis and increased prevention of relapses, reduction of disability, and reduction in total cost of care in the long-term, the incorporation of new agents into the treatment armamentarium of MS also poses challenges for patients, providers, caregivers, and MCOs as they have to make informed decisions based on the properties, risks, costs, and benefits of each drug. The opinions and practice patterns of national, regional, and local specialists must become a key piece of the evaluation process for newly approved drugs. As practice guidelines and practice patterns are developed and updated, MCOs must continue to evolve their formularies to appropriately cover medications for their members. This will require ongoing evaluation as new drugs for MS enter the marketplace. In addition, careful assessment of the risk-benefit profile of the various agents for relapsing MS should include an individualized approach for each patient as part of a shared decision-making process and take quality measures and outcomes into consideration. Case management and collaborative practice models such as DTM programs, which incorporate self-management, medication therapy, formulary management, and continuous education while promoting symptom management, medication adherence, and a health-promoting lifestyle, are important in the overall management of MS and can provide outcomes-based interventions aimed at controlling costs while maximizing treatment efficacy.
Managed Care Pharmacy Perspectives: Evaluating Risks Versus Benefits to Optimize Outcomes
Current and future DMTs for MS have many benefits in the treatment, modification, and progression of the disease. With these benefits come risks such as side effects, interactions, complications with future therapies, and antibody development. It is very important to evaluate each patient for the most appropriate treatment course and ensure that all risks and benefits of that course are weighed prior to starting therapy.
Of the current DMTs, there is an array of mechanisms, side effects, and efficacy in the various types of MS. Some of the medications can lead to antibody development and therefore may cause future therapies to be unusable. It is important to evaluate the patient to determine if, sometime in the future, other therapies may be necessary that would preclude the drug from being used. A similar issue arises when a medicationsuch as natalizumab-that can be an effective therapy is not safe in a subset of the patient population where available tests (e.g., JC-virus antibody test) can assess if the drug will be safe.
Some of the medications have potentially severe side effects, which require monitoring. With monitoring and safety programs, these valuable medications can enhance and prolong the remission rates in patients and keep them from progressing. It is important to remember that starting DMTs early may help to hold off progression of the disease so that patients with MS can live a fuller and more productive life for longer, rather than waiting until the disease progresses to start therapy due to potential avoidance of side effects. improve quality of care. 109 The data collected through disease management programs or ACOs (e.g., process and outcomes metrics) can be used to conduct comparative effectiveness research to evaluate the treatment and to ensure quality care is provided to patients with MS.
The cost of DMTs is expected to remain high, and with more DMTs slated for approval, MCOs will need to be proactive in collecting the information needed to make clinically sound decisions.
Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple Sclerosis
